Lisa Vermunt
Overview
Explore the profile of Lisa Vermunt including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
47
Citations
1207
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Dijkstra J, Vermunt L, Venkatraghavan V, Ozhegov G, Coomans E, Ossenkoppele R, et al.
Alzheimers Res Ther
. 2025 Mar;
17(1):57.
PMID: 40051009
Background: Rare variants of the triggering receptor expressed on myeloid cell 2 (TREM2) gene are strong risk factors for Alzheimer's disease (AD), and drugs targeting the TREM2 protein are being...
2.
Bolsewig K, Willemse E, Sanchez-Juan P, Rabano A, Martinez M, Doecke J, et al.
Nat Commun
. 2025 Jan;
16(1):1139.
PMID: 39881147
DOPA Decarboxylase (DDC) has been proposed as a cerebrospinal fluid (CSF) biomarker with increased concentrations in Lewy body disorders (LBDs) and highest levels in patients receiving dopaminergic treatment. Here we...
3.
Del Campo M, Quesada C, Vermunt L, Peeters C, Hok-A-Hin Y, Trieu C, et al.
Mol Neurodegener
. 2024 Nov;
19(1):82.
PMID: 39523360
This preclinical AD CSF proteome study identified a panel of 12-CSF markers detecting amyloid positivity and clinical progression to AD with high accuracy; some of these CSF proteins related to...
4.
Vermunt L, Sutphen C, Dicks E, de Leeuw D, Allegri R, Berman S, et al.
Brain Commun
. 2024 Oct;
6(5):fcae357.
PMID: 39440304
The grey matter of the brain develops and declines in coordinated patterns during the lifespan. Such covariation patterns of grey matter structure can be quantified as grey matter networks, which...
5.
van Lierop Z, Wessels M, Lekranty W, Moraal B, Hof S, Hogenboom L, et al.
Mult Scler
. 2024 Oct;
30(13):1620-1629.
PMID: 39420574
Background And Objectives: Serum neurofilament light (sNfL) is a biomarker for neuro-axonal damage in multiple sclerosis (MS). Clinical implementation remains limited. We investigated the impact of implementation on clinical decisions...
6.
Gogishvili D, Honey M, Verberk I, Vermunt L, Hol E, Teunissen C, et al.
J Neurochem
. 2024 Sep;
169(1):e16226.
PMID: 39289040
Glial fibrillary acidic protein (GFAP) is a well-established biomarker of reactive astrogliosis in the central nervous system because of its elevated levels following brain injury and various neurological disorders. The...
7.
Hok-A-Hin Y, Vermunt L, Peeters C, van der Ende E, de Boer S, Meeter L, et al.
medRxiv
. 2024 Sep;
PMID: 39228745
Diagnosis of Frontotemporal dementia (FTD) and the specific underlying neuropathologies (frontotemporal lobar degeneration; FTLD- Tau and FTLD-TDP) is challenging, and thus fluid biomarkers are needed to improve diagnostic accuracy. We...
8.
Ritchie C, Blennow K, Gispert J, Johnson S, van Maurik I, Vermunt L, et al.
Front Neurosci
. 2024 Jul;
18:1339742.
PMID: 38994272
No abstract available.
9.
Labib H, Tjerkstra M, Teunissen C, Horn J, Vermunt L, Coert B, et al.
World Neurosurg
. 2024 Jun;
189:e238-e252.
PMID: 38866237
Background: Neurofilament light chain (NfL), a biomarker reflecting neuro-axonal damage, may be useful in improving clinical outcome prediction after aneurysmal subarachnoid hemorrhage (aSAH). We explore the robust and additional value...
10.
Iyer A, Vermunt L, Mirfakhar F, Minaya M, Acquarone M, Koppisetti R, et al.
medRxiv
. 2024 May;
PMID: 38798451
Neuronal dysfunction has been extensively studied as a central feature of neurodegenerative tauopathies. However, across neurodegenerative diseases, there is strong evidence for active involvement of immune cells like microglia in...